In this two-part podcast, Professor Paul G. Richardson talks about the latest clinical and research developments with novel therapies in multiple myeloma. In part one he discusses the current use of proteosome inhibitors such as bortezomib (Velcade), particularly in relation to partnering therapy and the question of class switching.

In part two, Professor Richardson looks at novel therapies for MM such as the “game changing” impact of daratumumab (Darzalex) in early relapse. He also describes the rapidly changing research outlook for MM, including targeting of BCMA, adoptive cell therapy, CAR T-Cell therapy, smaller molecules approaches and novel cytotoxics.

Professor Richardson trained at Barts Hospital and the Royal Marsden Hospital in London and is now R.J. Corman Professor of Medicine at Harvard Medical School and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston.

This podcast was sponsored by Janssen. The content is based on published studies and the opinions of independent experts. The views expressed are not necessarily those of Janssen.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au).